Welcome to our dedicated page for Medicus Pharma news (Ticker: MDCX), a resource for investors and traders seeking the latest updates and insights on Medicus Pharma stock.
Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech and life sciences company whose news flow centers on clinical trial progress, regulatory milestones, strategic collaborations and capital markets activity. The company describes itself as a precision guided biotech/life sciences organization focused on advancing SkinJect™, an investigational microneedle therapy for basal cell carcinoma (BCC) of the skin, and Teverelix, a long-acting GnRH antagonist for hormone-driven conditions.
News updates frequently cover the SkinJect™ program, including Phase 2 study SKNJCT-003 in the United States, regulatory and ethics approvals to expand into the United Kingdom, and SKNJCT-004 in the United Arab Emirates. Releases also highlight interactions with the U.S. Food and Drug Administration (FDA), such as Type C meeting feedback supporting a 505(b)(2) regulatory pathway and the filing of an FDA Commissioner’s National Priority Voucher (CNPV) application for SKNJCT-003.
Another major theme in MDCX news is the Teverelix pipeline, added through the acquisition of Antev Limited. Company communications describe prior Phase 1 and Phase 2a data, FDA guidance on Phase 3 design, and plans to use AI-enabled analytics—via an engagement with Reliant AI Inc.—to support upcoming Teverelix clinical studies. Additional coverage includes Phase 1 data in healthy female volunteers and acceptance of Teverelix research for presentation at a leading endocrinology conference.
Investors following MDCX news will also see announcements on collaborations, such as the Gorlin Syndrome Alliance partnership for compassionate access to SkinJect™ and a non-binding memorandum of understanding with Helix Nanotechnologies, Inc. around thermostable infectious disease vaccines. Capital markets updates, including warrant inducement agreements, standby equity purchase activity and debenture financings, are disclosed through press releases and Form 8-K filings.
This news page aggregates these developments so readers can review Medicus Pharma’s clinical, regulatory, partnering and financing announcements in one place.
Medicus Pharma (NASDAQ: MDCX) reported independent KOL validation of its Phase 2 SKNJCT-003 SkinJect dataset on March 30, 2026. The 200µg cohort showed ~80% overall response rate, 73% clinical clearance, and 40% histological clearance at Day 57, supporting selection of the 200µg lead dose.
Dr. Babar Rao described the results as clinically meaningful and supportive of continued development and regulatory engagement for a potential non-surgical BCC treatment.
Medicus Pharma (NASDAQ: MDCX) will host a business update on March 26, 2026, highlighting Phase 2 SkinJect data and AI plans. The 200µg cohort showed an 80% overall response rate (ORR) at Day 57, with 73% clinical clearance and 40% histological complete response.
The company plans an End-of-Phase 2 FDA discussion, is advancing an agentic AI clinical platform, and reported $8.7 million in cash at year-end 2025 after raising ~$31.9 million in 2025.
Medicus Pharma (NASDAQ:MDCX) reported FY2025 results and a corporate update on March 25, 2026, highlighting a completed 90-patient Phase 2 SkinJect study with up to 73% clearance in the 200µg cohort and strengthened capital via ~$31.9M financing proceeds.
FY2025 financials: cash $8.7M, operating expenses $34.4M, net loss $35.4M, and disclosed substantial doubt about going concern; 2026 catalysts include an End-of-Phase 2 FDA meeting and initiation of Teverelix Phase 2b studies.
Medicus Pharma (NASDAQ:MDCX) will host a live fireside chat on March 19, 2026 to review positive Phase 2 SkinJect (SKNJCT-003) topline results.
Key data: 73% clinical clearance in the 200-µg D-MNA arm at Day 57 versus 38% in the device-only P-MNA control, supporting further development and regulatory discussions.
Medicus Pharma (NASDAQ: MDCX) announced that Dr. Babar K. Rao will provide clinical interpretation of positive Phase 2 SkinJect (SKNJCT-003) topline data during a business webcast on March 26, 2026. The randomized, double-blind study showed 73% clinical clearance in the 200-µg D-MNA arm vs 38% in the device-only arm at Day 57, with 40% histological clearance in the active cohort. Management views the dataset as decision-grade evidence to pursue regulatory discussions and potential strategic partnerships.
Medicus Pharma (NASDAQ:MDCX) announced that Dr. Raza Bokhari, Executive Chairman & CEO, will participate in the Longwood Miami CEO Forum on March 11-13, 2026 at the Ritz-Carlton Key Biscayne. He will join a panel titled "Accelerating the Path to Patient Care" to discuss the company's AI-enabled drug development strategy.
The invitation-only event gathers life sciences leaders for panels, fireside chats, and roundtables; notable participants include senior leaders from Pfizer, GSK, Editas, and others.
Medicus Pharma (NASDAQ: MDCX) reported Phase 2 SKNJCT-003 topline results for SkinJect: the 200-µg cohort achieved 73% clinical clearance and 40% histological clearance at Day 57, versus 38% clinical clearance in the P-MNA arm. The company calls the dataset decision-grade and plans an End-of-Phase-2 meeting with the FDA and to pursue partnering discussions.
Medicus also noted UK regulatory approvals to expand SKNJCT-003, completed U.S. enrollment of 90 patients, and recent corporate development activities including an August 2025 MoU and acquisitions.
Medicus Pharma (NASDAQ: MDCX) reported Phase 2 SKNJCT-003 topline results showing the 200µg D-MNA cohort reached 73% clinical clearance and 40% histological clearance (CR) at Day 57. The randomized, placebo-controlled study enrolled 90 patients; final CSR is expected in Q2 2026 to support an end-of-Phase-2 meeting with the FDA.
Results improved from Day 29 to Day 57, the company says the dataset is decision-grade for partnering discussions but notes the study was not powered for registrational endpoints.
Medicus Pharma (NASDAQ: MDCX) announced participation in the 38th Annual Roth Conference March 22-24, 2026, with a Fireside Chat by Executive Chairman & CEO Dr. Raza Bokhari on March 24, 2026, 12:30pm PT. Topics include SkinJect in Gorlin Syndrome, AI-enabled drug development, Teverelix progress, partnering readiness, and one-on-one investor meetings.
Medicus Pharma (NASDAQ:MDCX) CEO Dr Raza Bokhari was interviewed on Bloomberg World on February 10, 2026, outlining the company's AI-driven drug development strategy and near-term clinical catalysts.
Management disclosed nearly $14 million of personal capital committed at $4 per share and highlighted a planned Phase 2 Skinject data readout in H1 2026 as a potential value catalyst.